Apnimed
Breathing New Life Into OSA & More
Cambridge, United States · Founded 2017 · $163.3M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- apnimed.com
- Total Funding
- $163.3M
- Last Round
- $79.8M Series CJan 2023
- Rounds
- 5
About
Apnimed is a clinical-stage biopharmaceutical company developing pharmacological treatments for obstructive sleep apnea (OSA). Founded in 2017 and headquartered in Cambridge, Massachusetts, the company's lead program AD109 is a combination of atomoxetine and oxybutynin targeting the pharyngeal muscles that cause airway collapse during sleep, offering a potential non-CPAP oral therapy for OSA.
Summary
Apnimed is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $163.3M in total across 5 rounds, most recently a $79.8M Series C round in Jan 2023. Investors include Healthcare Royalty Partners and Morningside Group.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2026
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...